Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Neuro-OncologyOpen Access

An International Novel Therapeutics Accelerator for Brain Tumours: Early Impact and Lessons Learned

View Full Paper
Ask AI
Bookmark
Share

Authors

CACharlotte AitkenKBKatie BushbyCGCamille Goetz

Discussion

Loading...

Member takes

Overview

BTR-NTA supports researchers in drug development for brain tumours, highlighting key challenges and insights.

Key Points

  • BTR-NTA supports therapeutic development, leading to significant insights and refinements for researchers.
  • Since 2023, 24 international groups joined, advancing 11 therapeutics, with an average program usefulness rating of 9.7.
  • Experts provide critical feedback and guidance, identifying common challenges in brain tumour therapy development.
  • The program aims to enhance the efficiency of translating research into clinical therapies for brain tumours.

Cite This Study

Aitken et al. (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d6478147ahttps://doi.org/10.1093/neuonc/noaf185.052
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1EP18.01 GLOBAL COLLABORATION TO SUPPORT THE TRANSLATION OF BRAIN TUMOUR THERAPIES: EARLY IMPACT AND LEARNINGS FROM A NOVEL THERAPEUTICS ACCELERATOR.2025
  2. 2BRAIN TUMOUR RESEARCH AND CLINICAL TRIALS ACTIVITY IN THE UK 2016-2024: INSIGHTS FROM THE TESSA JOWELL CENTRE OF EXCELLENCE PROGRAMME2025
  3. 3Challenges and Innovations in Paediatric Brain Tumour Treatments2025
  4. 4TRANSFORMING MOLECULAR NEUROPATHOLOGY FOR BRAIN TUMOUR PATIENTS IN THE UK: LESSONS FROM THE TESSA JOWELL CENTRE OF EXCELLENCE PROGRAMME2025
  5. 5Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU2026